Close Menu

Admit it -- you've probably at least considered buying Illumina stock since the company announced its acquisition of Solexa. Motley Fool has an article on Illumina's earnings with a quick analysis of the company's numbers and position in the competitive landscape. One interesting tidbit the story points out: "its bottom line was eroded by $8.7 million" thanks to the eagerness with which employees have been cashing in their stock options.

 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

New research shows that scientists need to do a better job of including a wider diversity of African genomes in their analyses, STAT says.

A new paper in Science shows that men are still winning a large majority of the most sought-after NIH grants.

Nature Research and the Estée Lauder Companies are awarding efforts to encourage girls to pursue careers in the STEM fields.

In Science this week: beneficial genetic variants inherited from archaic Neanderthal and Denisovan hominins, and more.